Efficacy and safety of transarterial chemoembolization with chemotherapy, PD-1/PD-L1 inhibitors, and tyrosine kinase inhibitors in unresectable intrahepatic cholangiocarcinoma

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 9

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastrointest Oncol. Sep 15, 2025; 17(9): 103816
Published online Sep 15, 2025. doi: 10.4251/wjgo.v17.i9.103816

Table 2 Comparison of short-term efficacy between the two groups, n (%)

ORR: Objective response rate; DCR: Disease control rate.

Citation: Chen X, Sun XH, Xiao Y, Zhang D, Lu XY, Fu CL, Bi C, Wang X. Efficacy and safety of transarterial chemoembolization with chemotherapy, PD-1/PD-L1 inhibitors, and tyrosine kinase inhibitors in unresectable intrahepatic cholangiocarcinoma. World J Gastrointest Oncol 2025; 17(9): 103816
URL: https://www.wjgnet.com/1948-5204/full/v17/i9/103816.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i9.103816

Chen X, Sun XH, Xiao Y, Zhang D, Lu XY, Fu CL, Bi C, Wang X. Efficacy and safety of transarterial chemoembolization with chemotherapy, PD-1/PD-L1 inhibitors, and tyrosine kinase inhibitors in unresectable intrahepatic cholangiocarcinoma. World J Gastrointest Oncol 2025; 17(9): 103816 [PMID: 40977651 DOI: 10.4251/wjgo.v17.i9.103816]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.